Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19462138 | 0.98 | KDM4E (0.52) | KDM4EATMARCA2ALDH1A1 | |
| SCHEMBL24175083 | 0.84 | AR (0.50) | KDM4EATMARCA2ALDH1A1 | |
| SCHEMBL10848119 | 0.82 | AR (0.49) | KDM4EATMARCA2ALDH1A1 | |
| SCHEMBL11155997 | 0.81 | AR (0.52) | KDM4EATMARCA2ALDH1A1 | |
| SCHEMBL1302701 | 0.80 | HTT (0.47) | ARCA2ALDH1A1HTTLMNA | |
| SCHEMBL11162193 | 0.80 | HTR2A (0.55) | ARACHECA9MAPTCYP19A1 | |
| SCHEMBL10854280 | 0.79 | AR (0.51) | ARCA2ALDH1A1HTTLMNA | |
| SCHEMBL2759472 | 0.79 | AR (0.49) | KDM4EATMARCA2ALDH1A1 | |
| SCHEMBL11663137 | 0.78 | AR (0.50) | KDM4EARCA2ALDH1A1HTT | |
| SCHEMBL11661599 | 0.78 | ALDH1A1 (0.50) | ARCA2ALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017180769-A1 | SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER | CAPTEN THERAPEUTICS INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-1347967-B1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7192950-B2 | Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-03-20 | — | — | US | disclosed |
| US-20040058912-A1 | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-25 | — | — | US | disclosed |
| EP-1347967-A1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051838-A1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051232-A2 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2002-07-04 | — | — | WO | disclosed |
| US-4415591-A | MIXTURE WITH A MONOAMINE OXIDASE | GEORGIA TECH RESEARCH INSTITUTE (US) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058912-A1 | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | KDM4E 1024/4885ATM 4723/4885AR 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.